Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 7/20 | 0.39 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
| ▸ | PSMB8 | P28062 | 8/20 | 0.36 |
| ▸ | PSMB5 | P28074 | 7/20 | 0.36 |
| ▸ | PSMB2 | P49721 | 3/20 | 0.36 |
| ▸ | PSMB10 | P40306 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PSMB9 | P28065 | 3/20 | 0.36 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25500051 | 0.93 | MMP1 (0.39) | MMP1MMP3PSMB8PSMB5PSMB2 | |
| SCHEMBL23080567 | 0.93 | MMP1 (0.39) | MMP1MMP3PSMB8PSMB5PSMB2 | |
| SCHEMBL25444781 | 0.90 | MMP1 (0.42) | MMP1MMP3PSMB8PSMB5PSMB2 | |
| SCHEMBL25495881 | 0.87 | HTRA1 (0.40) | MMP1MMP3KMT2A | |
| SCHEMBL25447896 | 0.87 | MMP1 (0.38) | MMP1MMP3PSMB8PSMB5PSMB2 | |
| SCHEMBL23565378 | 0.84 | MMP1 (0.42) | MMP1PSMB8PSMB5PSMB2PSMB10 | |
| SCHEMBL23051829 | 0.83 | CACNA1B (0.46) | KMT2A | |
| SCHEMBL25495864 | 0.83 | P2RX7 (0.44) | — | |
| SCHEMBL25500045 | 0.83 | MMP1 (0.40) | MMP1MMP3PSMB8PSMB5PSMB2 | |
| SCHEMBL23537868 | 0.81 | HTRA1 (0.40) | MMP1MMP3PSMB8PSMB5PSMB10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577259-B2 | PCSK9 antagonist compounds | MERCK SHARP & DOHME LLC (US) | 2026-03-17 | — | — | US | disclosed |
| US-20230165932-A1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME LLC | 2023-06-01 | — | — | US | disclosed |
| US-20230165932-A1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME LLC | 2023-06-01 | — | — | US | disclosed |
| US-20230159592-A1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME LLC | 2023-05-25 | — | — | US | disclosed |
| US-20230159592-A1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME LLC | 2023-05-25 | — | — | US | disclosed |
| US-20230144324-A1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME LLC | 2023-05-11 | — | — | US | disclosed |
| US-20210069288-A1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME LLC | 2021-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210069288-A1 | PCSK9 ANTAGONIST COMPOUNDS | PCSK9, PCSK7, PCSK6 | MMP1 1262/4885MMP3 336/4885PSMB8 2534/4885 |
| US-20230165932-A1 | PCSK9 ANTAGONIST COMPOUNDS | PCSK9, PCSK7, PCSK6 | MMP1 1262/4885MMP3 336/4885PSMB8 2534/4885 |
| US-20230159592-A1 | PCSK9 ANTAGONIST COMPOUNDS | PCSK9, PCSK7, PCSK6 | MMP1 2039/4885MMP3 695/4885PSMB8 2632/4885 |
| US-12577259-B2 | PCSK9 antagonist compounds | PCSK9, LDLR, PCSK6 | MMP1 2003/4885MMP3 654/4885PSMB8 2561/4885 |
| US-20230144324-A1 | PCSK9 ANTAGONIST COMPOUNDS | PCSK9, PCSK7, PCSK6 | MMP1 865/4885MMP3 238/4885PSMB8 2560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.